With the availability of disease-modifying therapies for Alzheimer’s disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment.
High-throughput, mass spectrometry-based assays were used to measure %p-tau217 and amyloid beta (Aβ)42/40 ratio in blood samples from 583 individuals with suspected AD (53% positron emission tomography [PET] positive by Centiloid > 25). An algorithm (PrecivityAD2 test) was developed using these plasma biomarkers to identify brain amyloidosis by PET.
The area under the receiver operating characteristic curve (AUC-ROC) for %p-tau217 (0.94) was statistically significantly higher than that for p-tau217 concentration (0.91). The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2, was 0.94, yielding 88% agreement with amyloid PET. Diagnostic performance of the APS2 was similar by ethnicity, sex, age, and apoE4 status.
The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Matthew R. Meyer,
Kristopher M. Kirmess,
Stephanie Eastwood,
Traci L. Wente‐Roth,
Faith Irvin,
Mary S. Holubasch,
Venky Venkatesh,
Ilana Fogelman,
Mark Monane,
Lucy Hanna,
Gil D. Rabinovici,
Barry A. Siegel,
Rachel A. Whitmer,
Charles Apgar,
Randall J. Bateman,
David M. Holtzman,
Michael Irizarry,
David Verbel,
Pallavi Sachdev,
Satoshi Ito,
John Contois,
Kevin E. Yarasheski,
Joel B. Braunstein,
Philip B. Verghese,
Tim West | March 16, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents